NASDAQ · GPCR
Healthcare · Biotechnology
$27.47
Down-$0.12 (-0.43%)
Updated Oct 7, 2026, 3:21 AM
SID Score
3.8/10
Composite research score
Smart Money
53/100
Neutral
Price performance · GPCR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
GPCR closed at $27.47 after 21 trading sessions, down 31.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $27.55 | $27.8457 | $26.69 | $27.47 | 1.42M |
| Oct 5, 2026 | $28.10 | $28.205 | $26.41 | $27.59 | 1.87M |
| Oct 2, 2026 | $28.99 | $29.2466 | $27.5701 | $27.67 | 1.72M |
| Oct 1, 2026 | $31.27 | $31.39 | $28.93 | $28.98 | 2.59M |
| Sep 30, 2026 | $33.05 | $33.05 | $31.08 | $31.27 | 2.2M |
| Sep 29, 2026 | $34.78 | $34.9299 | $32.44 | $32.69 | 1.73M |
| Sep 28, 2026 | $34.86 | $35.64 | $34.43 | $35.065 | 1.28M |
| Sep 25, 2026 | $36.29 | $37.20 | $35.50 | $35.93 | 1.59M |
| Sep 24, 2026 | $35.35 | $36.27 | $34.43 | $36.02 | 2.11M |
| Sep 23, 2026 | $36.50 | $37.30 | $34.96 | $35.95 | 1.4M |
| Sep 22, 2026 | $36.99 | $37.74 | $36.25 | $36.91 | 612.1K |
| Sep 21, 2026 | $35.34 | $36.99 | $35.00 | $36.81 | 1.02M |
| Sep 18, 2026 | $35.04 | $35.6313 | $34.415 | $35.00 | 1.55M |
| Sep 17, 2026 | $36.05 | $36.45 | $35.0492 | $35.10 | 1.18M |
| Sep 16, 2026 | $39.19 | $39.19 | $35.42 | $35.50 | 1.65M |
| Sep 15, 2026 | $38.36 | $39.03 | $37.75 | $38.95 | 1.47M |
| Sep 14, 2026 | $38.92 | $39.24 | $37.8201 | $38.44 | 1.5M |
| Sep 11, 2026 | $39.82 | $40.27 | $38.10 | $38.66 | 1.28M |
| Sep 10, 2026 | $40.51 | $40.90 | $39.29 | $39.55 | 761.49K |
| Sep 9, 2026 | $41.23 | $44.94 | $40.49 | $41.23 | 1.56M |
| Sep 8, 2026 | $46.84 | $47.375 | $40.26 | $40.38 | 3.42M |
The latest Smart Investors Daily articles mentioning GPCR.
Company
Market Activity
Research & News
GPCR research
Company profile and research snapshot.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Citizens | Market Outperform | — |
| Aug 7, 2026 | Citigroup | Buy | — |
| Aug 7, 2026 | Citizens | Market Outperform | — |
| Jun 11, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 27, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 30, 2026
NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.
Yahoo · Sep 23, 2026
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.
Yahoo · Sep 22, 2026
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger.
Yahoo · Sep 22, 2026
Structure Therapeutics (GPCR) has put fresh clinical data for its oral obesity pipeline in front of investors, highlighting results from early stage ACCG-2671 studies and longer term aleniglipron weight loss trials. Recent trading tells a mixed story for Structure Therapeutics. The 1-day share price return of 5.17% to US$36.81 came after a year-to-date share price decline of 45.96%. Meanwhile, the 1-year total shareholder return of 50.55% points to strong longer term momentum that has cooled...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GPCR.
